Efficacy and Safety of RTH258 Versus Aflibercept - Study 2

NCT02434328 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1048

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-Related Macular Degeneration
Choroidal Neovascularization

Interventions

DRUG: Brolucizumab ophthalmic solution
DRUG: Aflibercept ophthalmic solution

Sponsor

Alcon Research